Varinos

Founded in 2017 and based in Tokyo, Japan, Varinos Inc. , d. b. a Varinos, a startup specializing in genome analysis.

The company develops and offers clinical tests that leverage genomic technology for infertility treatments in reproductive medicine, dental care abroad, and personalized medicine. In May 2026, Varinos Inc. raised an undisclosed amount  in series D funding led by Miraisozo Investments and Resona Bank, with participation from Mitsui Chemicals, Yokohama Capital, Shizuoka Bank, Shoko Chukin Bank, Joyo Bank and Higashi-Nippon Bank. The round was part of a larger JPY 1.

25 billion series D and debt funding. Varinos株式会社 specializes in the development and clinical implementation of genetic testing solutions utilizing advanced genomic technologies. The company's core product offerings include a range of genetic tests focused on infertility, reproductive health, and microbiome analysis, particularly uterine flora assessments and preimplantation genetic testing. These services aim to address societal issues such as infertility and declining birth rates by providing personalized insights that assist families in making informed decisions regarding their reproductive health.

Varinos serves healthcare providers, fertility clinics, and individual consumers, delivering tailored genomic information that aids in understanding and interpreting specific genetic results. The company markets its products primarily within Japan, with potential outreach to other regions as it expands its base of operations. The revenue model of Varinos株式会社 is structured around direct-to-consumer sales and B2B partnerships with healthcare providers and fertility clinics. Clients engage with the firm through purchasing specific genetic testing services or partnering for comprehensive analysis solutions.

Transactions typically involve individual payments for services rendered, such as uterine flora tests and preimplantation genetic tests, tailored to the unique needs of each client. Pricing structures are designed to provide accessible solutions for different consumer segments while ensuring high-quality and precise testing outcomes. Additionally, ongoing collaborations with medical professionals enhance the company's outreach and service offerings, reinforcing its position in the reproductive health market. The company plans to use the May 2026 funding to grow new businesses, expand market share locally and internationally, and improve testing quality.